1. Department of Hepatobiliary Surgery 2. Surgical Intensive Care Unit, the First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an 710061, China 3. Department of Obstetrics and Gynecology, Kansas University, Kansas City, KS 66160, USA
Accelerated senescence is important because this process is involved in tumor suppression and has been induced by many chemotherapeutic agents. The platinum-based chemotherapeutic agent cisplatin displays a wide range of antitumor activities. However, the molecular mechanism of cisplatin-induced accelerated senescence in hepatocellular carcinoma (HCC) remains unclear. In the present study, the growth inhibitory effect of cisplatin on HepG2 and SMMC-7721 cells was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cellular senescence was then assessed by β-galactosidase assay. Senescence-related factors, including p53, p21, and p16, were evaluated by quantitative reverse transcription-polymerase chain reaction. Reactive oxygen species (ROS) was analyzed by flow cytometry. Our results revealed that cisplatin reduced the proliferation of HepG2 and SMMC-7721 cells in a dose- and time-dependent manner. Senescent phenotype observed in cisplatin-treated hepatoma cells was dependent on p53 and p21 activation but not on p16 activation. Furthermore, cisplatin-induced accelerated senescence depended on intracellular ROS generation. The ROS scavenger N-acetyl-L-cysteine also significantly suppressed the cisplatin-induced senescence of HepG2 and SMMC-7721 cells. In conclusion, our results revealed a functional link between intracellular ROS generation and cisplatin-induced accelerated senescence, and this link may be used as a potential target of HCC.
HayflickL. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res1965; 37(3): 614-636 doi: 10.1016/0014-4827(65)90211-9 pmid: 14315085
2
DimriGP, LeeX, BasileG, AcostaM, ScottG, RoskelleyC, MedranoEE, LinskensM, RubeljI, Pereira-SmithO. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA1995; 92(20): 9363-9367 doi: 10.1073/pnas.92.20.9363 pmid: 7568133
3
ChangBD, BroudeEV, DokmanovicM, ZhuH, RuthA, XuanY, KandelES, LauschE, ChristovK, RoninsonIB. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res1999; 59(15): 3761-3767 pmid: 10446993
4
te PoeleRH, OkorokovAL, JardineL, CummingsJ, JoelSP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res2002; 62(6): 1876-1883 pmid: 11912168
5
FangK, ChiuCC, LiCH, ChangYT, HwangHT. Cisplatin-induced senescence and growth inhibition in human non-small cell lung cancer cells with ectopic transfer of p16INK4a. Oncol Res2007; 16(10): 479-488 doi: 10.3727/096504007783338331 pmid: 18196872
6
WangX, WongSC, PanJ, TsaoSW, FungKH, KwongDL, ShamJS, NichollsJM. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res1998; 58(22): 5019-5022 pmid: 9823301
7
PanieriE, GogvadzeV, NorbergE, VenkateshR, OrreniusS, ZhivotovskyB. Reactive oxygen species generated in different compartments induce cell death, survival, or senescence. Free Radic Biol Med2013; 57: 176-187 doi: 10.1016/j.freeradbiomed.2012.12.024 pmid: 23295411
QuK, XuX, LiuC, WuQ, WeiJ, MengF, ZhouL, WangZ, LeiL, LiuP. Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma. Cancer Lett2013; 331(1): 105-114 doi: 10.1016/j.canlet.2012.12.008 pmid: 23262037
10
RobersonRS, KussickSJ, VallieresE, ChenSY, WuDY. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res2005; 65(7): 2795-2803 doi: 10.1158/0008-5472.CAN-04-1270 pmid: 15805280
11
ColavittiR, FinkelT. Reactive oxygen species as mediators of cellular senescence. IUBMB Life2005; 57(4-5): 277-281 doi: 10.1080/15216540500091890 pmid: 16036611
12
IshikawaF. Cellular senescence, an unpopular yet trustworthy tumor suppressor mechanism. Cancer Sci2003; 94(11): 944-947 doi: 10.1111/j.1349-7006.2003.tb01382.x pmid: 14611669
ColladoM, SerranoM. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer2010; 10(1): 51-57 doi: 10.1038/nrc2772 pmid: 20029423
15
XueW, ZenderL, MiethingC, DickinsRA, HernandoE, KrizhanovskyV, Cordon-CardoC, LoweSW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature2007; 445(7128): 656-660 doi: 10.1038/nature05529 pmid: 17251933
16
JonesKR, ElmoreLW, Jackson-CookC, DemastersG, PovirkLF, HoltSE, GewirtzDA. p53-Dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol2005; 81(6): 445-458 doi: 10.1080/09553000500168549 pmid: 16308915
17
SantarosaM, Del ColL, ToninE, CaragnanoA, VielA, MaestroR. Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers. Mol Cancer Ther2009; 8(4): 844-854 doi: 10.1158/1535-7163.MCT-08-0951 pmid: 19372557
PetrosWP, BroadwaterG, BerryD, JonesRB, VredenburghJJ, GilbertCJ, GibbsJP, ColvinOM, PetersWP. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res2002; 8(3): 698-705 pmid: 11895898
20
SchmittCA, FridmanJS, YangM, LeeS, BaranovE, HoffmanRM, LoweSW. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell2002; 109(3): 335-346 doi: 10.1016/S0092-8674(02)00734-1 pmid: 12015983
21
ChangBD, XuanY, BroudeEV, ZhuH, SchottB, FangJ, RoninsonIB. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene1999; 18(34): 4808-4818 doi: 10.1038/sj.onc.1203078 pmid: 10490814
22
ChenZ, TrotmanLC, ShafferD, LinHK, DotanZA, NikiM, KoutcherJA, ScherHI, LudwigT, GeraldW, Cordon-CardoC, PandolfiPP. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature2005; 436(7051): 725-730 doi: 10.1038/nature03918 pmid: 16079851
23
RayessH, WangMB, SrivatsanES. Cellular senescence and tumor suppressor gene p16. Int J Cancer2012; 130(8): 1715-1725 doi: 10.1002/ijc.27316 pmid: 22025288
24
SteinGH, DrullingerLF, SoulardA, DulićV. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol1999; 19(3): 2109-2117 pmid: 10022898
25
VigneronA, VousdenKH. p53, ROS and senescence in the control of aging. Aging (Albany NY)2010; 2(8): 471-474 pmid: 20729567
26
LimSC, ChoiJE, KangHS, HanSI. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int J Cancer2010; 126(7): 1582-1595 pmid: 19728331
